<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379221</url>
  </required_header>
  <id_info>
    <org_study_id>FDG20140012H</org_study_id>
    <nct_id>NCT02379221</nct_id>
  </id_info>
  <brief_title>Efficacy of Injected Local Anesthetic vs Topical Anesthetic in Cosmetic Injectable Fillers.</brief_title>
  <official_title>Efficacy of Injected Local Anesthetic vs Topical Anesthetic in Cosmetic Injectable Fillers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Grant U.S. Air Force Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>David Grant U.S. Air Force Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare two modalities of local anesthetic administration
      prior to the placement of cosmetic facial injectable fillers. Both short and long term pain
      perceptions for the facial filler procedure will be compared in patients receiving 4%
      Topicaine gel on half their face, and 20% benzocaine gel prior to 2% lidocaine 1:100k
      epinephrine nerve block injections on the other half of their face. The objective is to
      quantify the subjective pain experienced by these two modalities of local anesthetic during
      the procedure of Juvederm XC filler injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if local anesthesia injections will provide more
      profound analgesia than topical anesthesia during facial cosmetic filler injections. The
      study is a single group study design. The attending surgeon or residents will perform the
      procedure. Each procedure will start with a randomized coin flip to determine which side of
      the face will be anesthetized with local anesthesia or topical anesthesia. The head side of
      the coin will coincide with local anesthesia on the patient's right side. The tail of the
      coin will designate the patient's left side for local anesthetic injections.

      To evaluate whether the additional anesthesia of a nerve block brings more pain relief than
      the initial pain of receiving a nerve block, the pain value will be collected from each nerve
      block administered. Procedural injection pain data will be collected from the nerve blocked
      facial half and from the topical anesthetic facial half to provide a comparison of anesthesia
      during the procedure. The primary outcome will be the collection of &quot;overall&quot; pain data from
      each side of the face 5-10 minutes after the procedure. Facial anesthesia preference data
      will also be collected at one week post treatment to determine overall pain perceptions from
      each method of facial anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Anesthetic Preference</measure>
    <time_frame>one week post treatment</time_frame>
    <description>Patient will complete a questionnaire to evaluate his/her preference of anesthetic modality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Level Associated With the Local Anesthetic Injection</measure>
    <time_frame>5-10 minutes post-procedure</time_frame>
    <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection to the upper and lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Level Associated With the Local Topical Anesthetic</measure>
    <time_frame>5-10 min post procedure</time_frame>
    <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during application of topical anesthesia to the upper and lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Level Associated With Facial Filler Injection at the Upper Lip</measure>
    <time_frame>5-10 minutes post procedure</time_frame>
    <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection of HA filler to the upper lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Level Associated With Facial Filler Injection to the Lower Lip</measure>
    <time_frame>5-10 minutes post procedure</time_frame>
    <description>A mean level of pain for all participants completing the Visual Analog Scale (VAS) during injection of HA filler to the lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm. The total score was divided by 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Level Associated With Facial Filler Injection to the Nasolabial Fold</measure>
    <time_frame>5-10 minutes post procedure</time_frame>
    <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection of HA filler to the nasolabial fold. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Injectable / Topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectable</intervention_name>
    <description>20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection</description>
    <arm_group_label>Injectable / Topical</arm_group_label>
    <other_name>benzocaine gel-lidocaine-epinephrine nerve block injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical</intervention_name>
    <description>4% Topicaine gel</description>
    <arm_group_label>Injectable / Topical</arm_group_label>
    <other_name>topical anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  Patients with deepened labiomental folds or decreased lip volume and architecture who
             are scheduled to receive Juvederm XC injections in DGMC Oral &amp; Maxillofacial Surgery
             clinic.

        Exclusion Criteria:

          -  Pregnant or nursing

          -  History of any type of neuralgia or paresthesia, or paresis

          -  Allergy or contraindication to lidocaine or hyaluronic acid

          -  Use of hyaluronic acid in last 6 months

          -  Previous reaction to Juvederm or other hyaluronic acid based fillers

          -  Have an active inflammatory or infectious process at the injection site.

          -  Use of monoamine oxidase (MAO) inhibitors or tricyclic antidepressants

          -  Severe coronary artery disease

          -  Diagnosis of any cardiac dysrhythmia with an ECG finding other than normal sinus
             rhythm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Diepenbrock, DDS</last_name>
    <role>Study Chair</role>
    <affiliation>USAF David Grant Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USAF David Grant Medical Center</name>
      <address>
        <city>Travis Air Force Base</city>
        <state>California</state>
        <zip>94535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of Juvéderm injectable gel with and without lidocaine. J Cosmet Dermatol. 2009 Sep;8(3):205-10. doi: 10.1111/j.1473-2165.2009.00451.x.</citation>
    <PMID>19735519</PMID>
  </reference>
  <reference>
    <citation>Levy PM, De Boulle K, Raspaldo H. A split-face comparison of a new hyaluronic acid facial filler containing pre-incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of naso-labial folds. J Cosmet Laser Ther. 2009 Sep;11(3):169-73. doi: 10.1080/14764170902833142.</citation>
    <PMID>19337944</PMID>
  </reference>
  <reference>
    <citation>Levy PM, De Boulle K, Raspaldo H. Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone. Dermatol Surg. 2009 Feb;35 Suppl 1:332-6; discussion 337. doi: 10.1111/j.1524-4725.2008.01045.x.</citation>
    <PMID>19207322</PMID>
  </reference>
  <reference>
    <citation>Smith KC, Melnychuk M. Five percent lidocaine cream applied simultaneously to the skin and mucosa of the lips creates excellent anesthesia for filler injections. Dermatol Surg. 2005 Nov;31(11 Pt 2):1635-7.</citation>
    <PMID>16416650</PMID>
  </reference>
  <reference>
    <citation>López-Jornet P, Camacho-Alonso F, Martinez-Canovas A. Clinical evaluation of polyvinylpyrrolidone sodium hyaluronate gel and 0.2% chlorhexidine gel for pain after oral mucosa biopsy: a preliminary study. J Oral Maxillofac Surg. 2010 Sep;68(9):2159-63. doi: 10.1016/j.joms.2009.09.047. Epub 2010 Jun 11.</citation>
    <PMID>20538398</PMID>
  </reference>
  <reference>
    <citation>Kim YK, Kim SG, Kim JH. Altered sensation after orthognathic surgery. J Oral Maxillofac Surg. 2011 Mar;69(3):893-8. doi: 10.1016/j.joms.2010.10.025. Epub 2011 Jan 6.</citation>
    <PMID>21211888</PMID>
  </reference>
  <reference>
    <citation>Maria A, Malik M, Virang P. Comparison of primary and secondary closure of the surgical wound after removal of impacted mandibular third molars. J Maxillofac Oral Surg. 2012 Sep;11(3):276-83. doi: 10.1007/s12663-011-0287-9. Epub 2011 Sep 23.</citation>
    <PMID>23997477</PMID>
  </reference>
  <reference>
    <citation>Brajkovic D, Brkovic B, Milic M, Biocanin V, Krsljak E, Stojic D. Levobupivacaine vs. bupivacaine for third molar surgery: quality of anaesthesia, postoperative analgesia and local vascular effects. Clin Oral Investig. 2014;18(5):1481-8. doi: 10.1007/s00784-013-1114-0. Epub 2013 Oct 6.</citation>
    <PMID>24097340</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <results_first_submitted>December 6, 2016</results_first_submitted>
  <results_first_submitted_qc>September 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 24, 2018</results_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Injectable / Topical</title>
          <description>Half of the face is injected with local anesthesia, the other half is treated with topical anesthesia per randomized method.
Injectable: 20% benzocaine, 2% lidocaine 1:100k epinephrine nerve block injection
Topical: 4% Topicaine gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>one participant dropped out before follow up visit. We were not able to get complete data on this participant so we did not use their information</population>
      <group_list>
        <group group_id="B1">
          <title>Injectable / Topical</title>
          <description>Half of the face is injected with local anesthesia, the other half is treated with topical anesthesia by randomized method.
Injectable: 20% benzocaine, 2% lidocaine 1:100k epinephrine nerve block injection
Topical: 4% Topicaine gel</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>One participant dropped out before her follow up visit. We were not able to get complete data on this participant so we did not use her information.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="22" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>One participant dropped out before completing study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Anesthetic Preference</title>
        <description>Patient will complete a questionnaire to evaluate his/her preference of anesthetic modality.</description>
        <time_frame>one week post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Half of the face is injected with local anesthesia per randomized method.
Injectable: 2% lidocaine 1:100k epinephrine nerve block injection
Topical: 4% Topicaine gel</description>
          </group>
          <group group_id="O2">
            <title>Topical</title>
            <description>Half of the face is treated with topical anesthesia per randomized method
Topical application of 20% benzocaine
4% lidocaine gel</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Anesthetic Preference</title>
          <description>Patient will complete a questionnaire to evaluate his/her preference of anesthetic modality.</description>
          <units>participant preference selection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Level Associated With the Local Anesthetic Injection</title>
        <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection to the upper and lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
        <time_frame>5-10 minutes post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Upper Lip</title>
            <description>2% lidocaine and 1:100k epinephrine injected to the upper lip</description>
          </group>
          <group group_id="O2">
            <title>Lower Lip</title>
            <description>2% lidocaine and 1:100K epi injected to the lower lip</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Level Associated With the Local Anesthetic Injection</title>
          <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection to the upper and lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="2.35"/>
                    <measurement group_id="O2" value="1.89" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Level Associated With the Local Topical Anesthetic</title>
        <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during application of topical anesthesia to the upper and lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
        <time_frame>5-10 min post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Upper Lip</title>
            <description>20% benzocaine to the upper lip</description>
          </group>
          <group group_id="O2">
            <title>Lower Lip</title>
            <description>20% benzocaine to the lower lip</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Level Associated With the Local Topical Anesthetic</title>
          <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during application of topical anesthesia to the upper and lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread=".21"/>
                    <measurement group_id="O2" value="0.11" spread=".32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Level Associated With Facial Filler Injection at the Upper Lip</title>
        <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection of HA filler to the upper lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
        <time_frame>5-10 minutes post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Half of the face is injected with local anesthesia per randomized method.
Injectable: 2% lidocaine 1:100k epinephrine nerve block injection
Topical: 4% Topicaine gel</description>
          </group>
          <group group_id="O2">
            <title>Topical</title>
            <description>Half of the face is treated with topical anesthesia per randomized method
Topical application of 20% benzocaine
4% lidocaine gel</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Level Associated With Facial Filler Injection at the Upper Lip</title>
          <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection of HA filler to the upper lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="1.60"/>
                    <measurement group_id="O2" value="3.67" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Level Associated With Facial Filler Injection to the Lower Lip</title>
        <description>A mean level of pain for all participants completing the Visual Analog Scale (VAS) during injection of HA filler to the lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm. The total score was divided by 48.</description>
        <time_frame>5-10 minutes post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Half of the face is injected with local anesthesia per randomized method.
Injectable: 2% lidocaine 1:100k epinephrine nerve block injection
Topical: 4% Topicaine gel</description>
          </group>
          <group group_id="O2">
            <title>Topical</title>
            <description>Half of the face is treated with topical anesthesia per randomized method
Topical application of 20% benzocaine
4% lidocaine gel</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Level Associated With Facial Filler Injection to the Lower Lip</title>
          <description>A mean level of pain for all participants completing the Visual Analog Scale (VAS) during injection of HA filler to the lower lip. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm. The total score was divided by 48.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="2.41"/>
                    <measurement group_id="O2" value="4.38" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Level Associated With Facial Filler Injection to the Nasolabial Fold</title>
        <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection of HA filler to the nasolabial fold. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
        <time_frame>5-10 minutes post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Injectable</title>
            <description>Half of the face is injected with local anesthesia per randomized method.
Injectable: 2% lidocaine 1:100k epinephrine nerve block injection
Topical: 4% Topicaine gel</description>
          </group>
          <group group_id="O2">
            <title>Topical</title>
            <description>Half of the face is treated with topical anesthesia per randomized method
Topical application of 20% benzocaine
4% lidocaine gel</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Level Associated With Facial Filler Injection to the Nasolabial Fold</title>
          <description>Participant will complete a questionnaire to evaluate his/her pain level perception using a Visual Analog Scale (VAS) during injection of HA filler to the nasolabial fold. The Visual Analog scale uses a 10 cm horizontal line with 'no pain' labeled on the left end of line and 'worst pain' on the right end of line. Participant marks their pain level at any point on the line from no pain to worst pain. No pain= 0 cm, Worst pain=10cm</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="1.49"/>
                    <measurement group_id="O2" value="2.82" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Injectable / Topical</title>
          <description>One side of face is injected with local anesthesia, the other side is treated with topical anesthesia per randomization.
Injectable: 20% benzocaine, 2% lidocaine 1:100k epinephrine nerve block injection
Topical: 4% Topicaine gel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Syncopal Episode</sub_title>
                <description>Participant had just received his HA filler treatment when he had a syncopal episode. He was still sitting in chair it lasted approximately 30 seconds. He was treated per OMFS department protocol. He was fully recovered before he left the clinic.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jason May</name_or_title>
      <organization>Travis AFB OMFS Clinic</organization>
      <phone>707-423-7085</phone>
      <email>jason.may.11@us.af.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

